BioSpace News Archive

Business

Karmanos welcomes new VP of the Karmanos Cancer Network

The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN , MSA, as the vice president of the Karmanos Cancer Network, part of McLaren Health Care.

December 5, 2023
·
4 min read
Drug Development

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Trevi Therapeutics, Inc. today announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough.

December 5, 2023
·
6 min read
BioMidwest

Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System

Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact ® System in Japan beginning November 30, 2023.

December 5, 2023
·
5 min read
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Cybin Inc. today announced the presentation of four posters at the America College of Neuropsychopharmacology (“ACNP”) annual meeting taking place December 3-6, 2023, in Tampa, Florida.

December 5, 2023
·
9 min read
Biotech Bay

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. today announced that it has submitted an NDA for acoramidis to the U.S. FDA for the treatment of ATTR-CM.

December 5, 2023
·
7 min read
Job Trends

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity

Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available.

December 5, 2023
·
11 min read
Drug Development

Appia Bio to Present Data on API-192 at the 65th American Society for Hematology Annual Meeting and Exposition

Appia Bio today announced that it will present preclinical data on API-192, a first-in-class CAR-NKT allogeneic cell therapy for the treatment of a broad array of B-cell mediated malignancies including non-Hodgkin lymphoma, one of the most common cancers in the U.S.

December 5, 2023
·
3 min read
Drug Development

BioInvent Enrolls First Patient in Phase 1/2a Clinical Trial with TNFR2 Antibody BI-1910

BioInvent International AB today announces it has enrolled the first patient in its Phase 1/2a trial of the monoclonal antibody BI-1910, the company’s second anti-tumor necrosis factor receptor 2 (TNFR2) program to enter clinical development.

December 5, 2023
·
3 min read
Drug Development

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics, Inc. today announced that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm is the Company’s orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.

December 5, 2023
·
7 min read
Pharm Country

Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington’s Disease

Rumi Scientific (“Rumi”) today announced that it has entered into a partnership with X-Chem, the leading provider of innovative solutions in early-stage drug discovery, through which X-Chem will develop a lead candidate BRD9 inhibitor for the treatment of Huntington’s Disease (HD).

December 5, 2023
·
2 min read